title: The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.
abstract: Clinical trials utilising interleukin (IL)-2 with tumor-infiltrating lymphocytes (TIL) have demonstrated efficacy in the treatment of metastatic renal cell carcinoma (RCC). Several cytokines, as well as growth factors have demonstrated modulatory effects upon the biological properties of TIL from RCC, suggesting a potentially important role for cytokines other than IL-2 in the development of active and tumor-specific TIL. IL-12 was recently characterized as a natural-killer-cell-stimulatory factor or cytotoxic-T-cell-maturation factor. These properties of IL-12 prompted us to investigate the impact of this cytokine upon the activation of TIL from human RCC. In an attempt to enhance the in vitro growth and activity of renal TIL, we have grown eight renal TIL cultures in varying concentrations of IL-2 (8, 40, 80, 400 U/ml) and IL-12 (200 U/ml). In addition, IL-12 (200 U/ml) was added to TIL cultures pre-activated with IL-2 (400 U/ml). Growth, cell expansion, and the ability of TIL to release certain cytokines upon tumor stimulation were determined. Proliferation assays, phenotypic analysis, and cytotoxicity assays were performed at an early and a late culture stage. IL-12, alone and when added to suboptimal concentrations of IL-2, failed to induce TIL growth. While the addition of IL-12 to optimal doses of IL-2 suppressed TIL culture expansion, sequential culture exposure first to IL-2 and then to IL-2+IL-12 increased the number of cells expressing CD3+/CD56+ and these cultures demonstrated enhanced in vitro lysis of autologous tumor. IL-12 clearly demonstrated a sequence-dependent impact of the biological behaviour of TIL from RCC. The optimal use of IL-12 in the in vitro expansion of renal TIL may result in cells with an enhanced specific anti-tumor effect.
authors.affiliation: University of Vienna, Department of Internal Medicine I, Austria. guenther.steger@akh-wien.ac.at
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
authors.forename: M F
authors.initials: MF
authors.lastname: Gnant
authors.forename: M P
authors.initials: MP
authors.lastname: Djavanmard
authors.forename: R M
authors.initials: RM
authors.lastname: Mader
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
authors.forename: W
authors.initials: W
authors.lastname: Pierce
authors.forename: J B
authors.initials: JB
authors.lastname: deKernion
authors.forename: R
authors.initials: R
authors.lastname: Figlin
authors.forename: A
authors.initials: A
authors.lastname: Belldegrun
mesh_terms: D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D018664:Interleukin-12 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2; D018664:Interleukin-12